BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for...(bution of its products and that addition...),Health

Date:9/21/2009

bution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (filed November 28, 2008), Quarterly Reports on Form 10-Q, and current reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in our projections and forward-looking statements.

BCRXW

'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. BioCryst to Present at UBS Global Life Sciences Conference
2. BioCryst Announces Partnerships for Peramivir for Influenza Outside the U.S.
3. BioCryst Executives to Present at Two Investor Conferences
4. BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update
5. BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology
6. BioCryst to Present at the 11th Annual BIO CEO & Investor Conference
7. BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009
8. BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
9. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
10. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
11. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007